Chronic Back Pain Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

(Albany, United States) As per DelveInsight's assessment, globally, Chronic Back Pain pipeline constitutes key companies continuously working towards developing Chronic Back Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Chronic Back Pain Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Back Pain Market.

The Chronic Back Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Back Pain Pipeline Report:
• Chronic Back Pain Companies across the globe are diligently working toward developing novel Chronic Back Pain treatment therapies with a considerable amount of success over the years.
• Chronic Back Pain companies working in the treatment market are BDH Pharma, Synerkine Pharma, AnGes MG, Persica Pharmaceuticals, CHA Biotech, Eli Lilly and Company, Biogen, Mesoblast, Vertanical GmbH, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, and others, are developing therapies for the Chronic Back Pain treatment
• Emerging Chronic Back Pain therapies in the different phases of clinical trials are- BDH-001, SK-01, AMG0103, PP353, CordSTEM-DD, LY3857210, BIIB074, MPC-06-ID, VER-01, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), and others are expected to have a significant impact on the Chronic Back Pain market in the coming years.
• In January 2025, Mainstay Medical Holdings plc announced the release of favorable one-year primary assessment results from the RESTORE randomized clinical trial of ReActiv8 for treating intractable chronic low back pain. The data indicate that incorporating ReActiv8 Restorative Neurostimulation therapy into the current standard of care leads to significantly greater improvements in back pain-related disability, pain, and overall quality of life compared to standard treatments alone
• In November 2024, Contineum Therapeutics, Inc. (NASDAQ: CTNM) (referred to as Contineum or the Company), a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative oral small molecule therapies targeting biological pathways linked to specific clinical issues in neuroscience, inflammation, and immunology (NI&I), has announced that it has received authorization from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PIPE-791. This drug is intended for the treatment of chronic pain related to two distinct conditions: osteoarthritis (OA) and low back pain (LBP). PIPE-791 is a novel, brain-penetrating small molecule that acts as an antagonist to the lysophosphatidic acid 1 receptor (LPA1R).
• In September 2024, Spine BioPharma completed patient enrollment for its Phase III MODEL clinical trial of SB-01 For Injection, designed to treat chronic low back pain (CLBP) associated with degenerative disc disease (DDD).
• In July 2024, Australia-based Mesoblast initiated patient enrollment for the Phase III clinical trial of rexlemestrocel-L in individuals with chronic low back pain (CLBP) resulting from inflammatory degenerative disc disease. Rexlemestrocel-L is an allogeneic, immunoselected, and commercially manufactured stromal cell therapy.

Chronic Back Pain Overview
Chronic back pain is a persistent pain lasting more than 12 weeks, even after the initial injury or underlying cause has healed. It is a common condition affecting millions worldwide and can significantly impact daily activities, work productivity, and overall quality of life. Chronic back pain may originate from musculoskeletal, neurological, or structural issues, making diagnosis and treatment complex.

Common causes include degenerative disc disease, herniated discs, spinal stenosis, arthritis, muscle or ligament strain, and conditions like scoliosis or fibromyalgia. In some cases, no clear cause is identified, leading to a diagnosis of nonspecific chronic back pain. Symptoms range from dull, aching pain to sharp, shooting sensations, often worsening with movement or prolonged inactivity.

Diagnosis involves a thorough medical history, physical examination, and imaging tests like X-rays, MRI, or CT scans. Treatment varies based on the cause and severity, including physical therapy, pain medications (NSAIDs, muscle relaxants), lifestyle modifications, and minimally invasive procedures like injections. In severe cases, surgery may be considered. Complementary therapies such as acupuncture, chiropractic care, and mindfulness techniques can also help manage pain.

Long-term management focuses on improving mobility, reducing pain, and enhancing overall well-being through a multidisciplinary approach.

Get a Free Sample PDF Report to know more about Chronic Back Pain Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Chronic Back Pain Drugs Under Different Phases of Clinical Development Include:
• BDH-001: BDH Pharma
• SK-01: Synerkine Pharma
• AMG0103: AnGes MG
• PP353: Persica Pharmaceuticals
• CordSTEM-DD: CHA Biotech
• LY3857210: Eli Lilly and Company
• BIIB074: Biogen
• MPC-06-ID: Mesoblast
• VER-01: Vertanical GmbH
• Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.
• Semdexa (SP-102): Scilex Holding
• Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited

Chronic Back Pain Pipeline Therapeutics Assessment
• Chronic Back Pain Assessment by Product Type
• Chronic Back Pain By Stage and Product Type
• Chronic Back Pain Assessment by Route of Administration
• Chronic Back Pain By Stage and Route of Administration
• Chronic Back Pain Assessment by Molecule Type
• Chronic Back Pain by Stage and Molecule Type

DelveInsight's Chronic Back Pain Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Back Pain product details are provided in the report. Download the Chronic Back Pain pipeline report to learn more about the emerging Chronic Back Pain therapies at:
https://www.delveinsight.com/sample-request/chronic-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Chronic Back Pain Therapeutics Market include:
Key companies developing therapies for Chronic Back Pain are - Merck & Co., Medtronic, Boston Scientific Corporation, Johnson & Johnson Services Inc., Pfizer Inc, Vertebral Technologies, Inc., Mesoblast Limited, SpineThera, Stayble Therapeutics, Eli Lilly and Company, Persica Pharmaceuticals, and others.

Chronic Back Pain Pipeline Analysis:
The Chronic Back Pain pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Back Pain with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Back Pain Treatment.
• Chronic Back Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Back Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Back Pain market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Back Pain drugs and therapies-
https://www.delveinsight.com/sample-request/chronic-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Chronic Back Pain Pipeline Market Drivers
• Rise in Anti-inflammatory Medications, increase in Nerve Cases are some of the important factors that are fueling the Chronic Back Pain Market.

Chronic Back Pain Pipeline Market Barriers
• However, high Cost Associated with Drug Development, stringent Regulatory Policies and other factors are creating obstacles in the Chronic Back Pain Market growth.

Scope of Chronic Back Pain Pipeline Drug Insight
• Coverage: Global
• Key Chronic Back Pain Companies: BDH Pharma, Synerkine Pharma, AnGes MG, Persica Pharmaceuticals, CHA Biotech, Eli Lilly and Company, Biogen, Mesoblast, Vertanical GmbH, Camurus/Braeburn Inc., Scilex Holding, Mesoblast Limited, and others
• Key Chronic Back Pain Therapies: BDH-001, SK-01, AMG0103, PP353, CordSTEM-DD, LY3857210, BIIB074, MPC-06-ID, VER-01, Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Semdexa (SP-102), Rexlemestrocel-L (MPC-06-ID), and others
• Chronic Back Pain Therapeutic Assessment: Chronic Back Pain current marketed and Chronic Back Pain emerging therapies
• Chronic Back Pain Market Dynamics: Chronic Back Pain market drivers and Chronic Back Pain market barriers

Request for Sample PDF Report for Chronic Back Pain Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/chronic-back-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Chronic Back Pain Report Introduction
2. Chronic Back Pain Executive Summary
3. Chronic Back Pain Overview
4. Chronic Back Pain- Analytical Perspective In-depth Commercial Assessment
5. Chronic Back Pain Pipeline Therapeutics
6. Chronic Back Pain Late Stage Products (Phase II/III)
7. Chronic Back Pain Mid Stage Products (Phase II)
8. Chronic Back Pain Early Stage Products (Phase I)
9. Chronic Back Pain Preclinical Stage Products
10. Chronic Back Pain Therapeutics Assessment
11. Chronic Back Pain Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Chronic Back Pain Key Companies
14. Chronic Back Pain Key Products
15. Chronic Back Pain Unmet Needs
16 . Chronic Back Pain Market Drivers and Barriers
17. Chronic Back Pain Future Perspectives and Conclusion
18. Chronic Back Pain Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Phosphoglucomutase Pgm 1 Deficiency Market: https://www.delveinsight.com/report-store/phosphoglucomutase-pgm-1-deficiency-market
• Polypoidal Choroidal Vasculopathy Market: https://www.delveinsight.com/report-store/polypoidal-choroidal-vasculopathy-market
• Tay-sachs Disease Or Gm2 Gangliosidosis Market: https://www.delveinsight.com/report-store/tay-sachs-disease-pipeline-insight
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/report-store.php
AACR Conference Coverage: https://www.delveinsight.com/aacr-annual-meeting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.